An observational study in Microbiota, sponsored by First Affiliated Hospital of Harbin Medical University. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-14.
Sponsored by First Affiliated Hospital of Harbin Medical University · Observational
Among 19 studies in Graves Disease with a site in China — 10 open to participants now, 10 under way, 1 of them phase 3. Graves Disease · China.
Among the 19 studies in Graves Disease with a site in China, this one is one of 3 that started in 2017, is one of 9 observational ones, and was the 6th registered.
162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
Browse Graves Disease studies →10 of the 19 studies in Graves Disease with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Shanghai Changzheng Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Shanghai Zhongshan Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 1 · Phase 4 1
First in 2010; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 120 across 56 observational studies indexed under Graves Disease.
Median enrollment 37 across the 10 interventional studies, 200 across the 9 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 19 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Harbin Medical University is the lead sponsor of 74 studies on the registry; 11 are open to participants now.
First Affiliated Hospital of Harbin Medical University has 3 studies filed under Graves Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Graves Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07129642Shanghai Zhongshan HospitalAllogeneic Anti-CD19 CAR-T for Refractory Graves' Disease | 2026-12-31 |
| NCT07333677Shanghai Zhongshan HospitalIn Vivo CAR-T for Refractory Graves' Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Graves Disease with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls and analyse the relationship between intestinal microbiota and GD drug therapy.
Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls before and found that gut microbiota changed between GD patients and healthy controls.But there are few articles on the relationship between intestinal microbiota and drug treatment of GD, so Investigators explored the relationship between intestinal microflora and methimazole treatment for GD.
All patients were included according to the inclusion and exclusion criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
30 healthy volunteers were included in the healthy control group
30 GD patients who received recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
Drug: Methimazole Pill · Drug: Propylthiouracil Pill
30 GD patients who did not receive recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill
Drug: Methimazole Pill · Drug: Propylthiouracil Pill
Patients who developed GD received methimazole treatment
Patients who developed GD received propylthiouracil treatment
Transcriptional changes in gut microbiota
The microbiota measured by 16S rRNA gene
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal
Serum thyroid function changed
Serum thyroid function measured by Immunohistochemistry
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal
Serum thyroid related antibodies changed
Serum thyroid related antibodies measured by Immunohistochemistry
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal
Plan to share: No
Started Dec 2017 (actual). Primary completion is estimated for Dec 2018, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Harbin Medical University